German fintech platform Solarisbank AG opened an R&D office in Kyiv, Ukraine. Solarisbank is the first Banking-as-a-Service platform with a full banking license that enables companies to offer their
German fintech platform Solarisbank AG opened an R&D office in Kyiv, Ukraine. Solarisbank is the first Banking-as-a-Service platform with a full banking license that enables companies to offer their
The Ukrainian pharmaceutical company Farmak opens an office in the United Arab Emirates and plans to further strengthen its expansion in the Middle East and localization in Saudi Arabia and Egypt. In August, the
Ukrainian tech giant Intellias announced the opening the new office in Dnipro in the beginning of 2022. It will be the 6th R&D center in Ukraine in addition to Lviv, Kyiv, Odesa, Kharkiv, and Ivano-Frankinsk
German fintech platform Solarisbank AG opened an R&D office in Kyiv, Ukraine. Solarisbank is the first Banking-as-a-Service platform with a full banking license that enables companies to offer their own financial products
The USA streaming software giant Roku will open an R&D office in Kyiv. Now the company opened 2 positions Site Director and Senior Technical Recruite
For the last half-year international tech giants continue to open the R&Ds in Ukraine: BlaBlaCar, Glovo, Globality, Lyft, CognitOps. Even now Ukraine is home to more than 110 R&D centers for global tech giants including Microsoft, Samsung Electronics, Apple, Skype, IBM, The Boeing Company, Ericsson
Ukrainian ELEKS is launching its newest office in Zurich, Switzerland, continuing its global expansion and strengthening its presence within central Europe. Through the creation of this new Swiss hub, the company
Apple opened an official office in Ukraine. Through a future network of official dealers, Apple will sell
Apple opened an official office in Ukraine. Through a future network of official dealers, Apple will sell imported equipment and provide authorized service and parts
Pharmaceutical company Farmak is investing EUR 30 million in the construction of an innovative research R&D center in Kyiv. It is planned to continue working in three main areas: finished dosage forms, proprietary active pharmaceutical ingredients, as well as biotechnological active pharmaceutical ingredients